Plus Therapeutics (PSTV) Gains from Sales and Divestitures (2016 - 2026)
Plus Therapeutics (PSTV) reported Gains from Sales and Divestitures of $8867.0 for Q1 2026, down 95.95% quarter-over-quarter from $219193.0 in Q4 2025.
Plus Therapeutics (PSTV) Gains from Sales and Divestitures (2016 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 3 years of Gains from Sales and Divestitures data on file, last reported at $8867.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $8867.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $8867.0 (changed N/A YoY), and the FY2025 annual result was $219193.0, changed N/A from the prior year.
- Gains from Sales and Divestitures slipped to $8867.0 in Q1 2026 per PSTV's latest filing, from $219193.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $219193.0 in Q4 2025 and troughed at $8867.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Plus Therapeutics | 34.26 Mn | 19.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,867.00 |
| Mar 31, 2026 | 8,867.00 |
| Dec 31, 2025 | 219,193.00 |
| Dec 31, 2025 | 219,193.00 |
| Dec 31, 2016 | 11,568.00 |
| Dec 31, 2016 | 11,568.00 |